TY - JOUR
T1 - Chordoma combined with Trousseau syndrome
T2 - a case report and literature review
AU - Rao, Ruiying
AU - Lin, Ping
AU - Xu, Jinhe
AU - Wang, Chenxi
AU - Chen, Ying
AU - Ito, Shinji
AU - Mutoh, Tatsuro
AU - Yu, Zongyang
N1 - Publisher Copyright:
© AME Publishing Company.
PY - 2024/9/30
Y1 - 2024/9/30
N2 - Background: Trousseau syndrome (TS) refers to spontaneous, recurrent, and wandering arterial and venous thromboembolic events in patients with tumors. It results from abnormalities in coagulation and fibrinolytic mechanisms of varying degrees throughout the course of the disease. It has a high fatality rate, and it is commonly seen in patients with highly invasive tumors, such as lung, pancreatic, gastrointestinal, and breast cancers; however, to date, there has been no report of TS combined with chordoma. Case Description: A 56-year-old male with a diagnosis of chordoma underwent surgery, immunotherapy, immunotherapy combined with antiangiogenic therapy, chemotherapy combined with immunotherapy, and proton therapy for localized metastases. Subsequent to the worsening of chest tightness, a repeat chest computed tomography angiography (CTA) scan suggested pulmonary artery embolisms; eventually, a diagnosis of TS was made. After anticoagulation and synchronized antitumor therapy, the patient’s condition remained recurrent, eventually leading to death. Conclusions: TS is a frequent but easily overlooked clinical complication that can occur in a variety of tumors, including chordoma, and is currently diagnosed clinically. Thus, further exploration of its sensitive markers is needed. We have reported a case of chordoma combined with TS and conducted a literature review on TS to increase clinicians’ awareness of tumor-related thromboembolism and explore strategies to optimize the diagnosis, treatment, and prevention of TS.
AB - Background: Trousseau syndrome (TS) refers to spontaneous, recurrent, and wandering arterial and venous thromboembolic events in patients with tumors. It results from abnormalities in coagulation and fibrinolytic mechanisms of varying degrees throughout the course of the disease. It has a high fatality rate, and it is commonly seen in patients with highly invasive tumors, such as lung, pancreatic, gastrointestinal, and breast cancers; however, to date, there has been no report of TS combined with chordoma. Case Description: A 56-year-old male with a diagnosis of chordoma underwent surgery, immunotherapy, immunotherapy combined with antiangiogenic therapy, chemotherapy combined with immunotherapy, and proton therapy for localized metastases. Subsequent to the worsening of chest tightness, a repeat chest computed tomography angiography (CTA) scan suggested pulmonary artery embolisms; eventually, a diagnosis of TS was made. After anticoagulation and synchronized antitumor therapy, the patient’s condition remained recurrent, eventually leading to death. Conclusions: TS is a frequent but easily overlooked clinical complication that can occur in a variety of tumors, including chordoma, and is currently diagnosed clinically. Thus, further exploration of its sensitive markers is needed. We have reported a case of chordoma combined with TS and conducted a literature review on TS to increase clinicians’ awareness of tumor-related thromboembolism and explore strategies to optimize the diagnosis, treatment, and prevention of TS.
KW - Trousseau syndrome (TS)
KW - case report
KW - chordoma
KW - pulmonary embolism (PE)
KW - venous thrombosis
UR - http://www.scopus.com/inward/record.url?scp=85205367965&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85205367965&partnerID=8YFLogxK
U2 - 10.21037/jtd-24-1232
DO - 10.21037/jtd-24-1232
M3 - Article
AN - SCOPUS:85205367965
SN - 2072-1439
VL - 16
SP - 6249
EP - 6262
JO - Journal of Thoracic Disease
JF - Journal of Thoracic Disease
IS - 9
ER -